Lymphoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Bayer Healthcare Pharmaceuticals

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Lymphoma Clinical Trial

Schedule an Appointment